Our study aims were (1) to evaluate the association between CD24/CD11b expression and clinical measurements (background diseases, past cancer, family history of cancer, obesity), healthy behaviors (smoking, physical activity), and demographic characteristics (age, gender) among healthy participants and (2) to assess CD24/CD11b levels of participants with and without benign tumors. Here, CD24 is linked to benign neoplasm.